# Oncimmune Holdings plc Data presented at the 11th Annual ILCA

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-plc-data-presented-11th-annual-ilca/412735470
- Published: 2017-09-18T07:14:30+01:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON:ONC), a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT® platform technology, today announced
that data relating to the development of its EarlyCDT®-Liver panel was presented
at the 11th Annual International Liver Cancer Association (ILCA), which took place
from Friday 15th to Sunday 17th September 2017, in Seoul, South Korea.

A presentation called “Autoantibodies as additive biomarkers to AFP for the detection
of HCC” showed that a panel of 10 autoantibodies could detect hepatocellular carcinoma(
HCC) with high sensitivity and specificity. The test was also able to distinguish
HCC from patients with chronic liver disease regardless of stage or tumour size.

These results provided the data for Oncimmune to develop its next test to launch–
EarlyCDT-Liver – which is in its final stages of autoantibody panel selection and
validation. The test is expected to be launched in the first half of 2018 and will
significantly improve the performance of the current existing diagnostic test alpha
fetoprotein (AFP), which has come under scrutiny as the levels can be raised in 
many patients who have liver disease but not HCC.

> **Geoffrey Hamilton-Fairley, Oncimmune Holdings plc Chief Executive Officer, commented:**“
> The detection of hepatocellular carcinoma at an early stage is crucial for a positive
> outcome. It is an especially big problem in Asia, and in Asian populations in 
> Europe and America, where the incidence is many times that in the non-Asian populations
> due to Hepatitis B and C. Despite its low performance, many millions of AFP tests
> are carried out each year using a simple 96 well ELISA test similar to the EarlyCDT
> tests. The majority of hospitals worldwide have access to a 96 well ELISA reader
> and thus we believe that this better performing test should be welcomed throughout
> affected communities.”

Share on:
